Immuneering To Present at Guggenheim 2023 Oncology Conference

January 31, 2023

https://www.globenewswire.com/news-release/2023/01/31/2598224/0/en/Immuneering-To-Present-at-Guggenheim-2023-Oncology-Conference.html

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq:IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activating events, today announced that management will present at Guggenheim’s 2023 Oncology Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.

Read more at globenewswire.com

Related news for (IMRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.